Jessica Skarzynski


Prolonged Treatment With Darolutamide Is Well Tolerated in Nonmetastic CRPC

February 12th 2021

February 12, 2021 - The androgen receptor inhibitor darolutamide continues to show favorable tolerability in patients with nonmetastatic castration-resistant prostate cancer, even when given for a prolonged period of time.

Apatinib Plus Chemotherapy Shows Promising Efficacy, Tolerability in Pretreated SCLC

January 28th 2021

January 28, 2021 - The addition of apatinib to single agent chemotherapy showed promising efficacy and was found to be well tolerated in patients with pretreated advanced small cell lung cancer.

Lenvatinib and Pembrolizumab Combination Safe, Effective For Multiple Gastrointestinal Cancer Types

January 15th 2021

The combination of the anti-angiogenic multikinase inhibitor lenvatinib plus the anti-PD-1 antibody pembrolizumab demonstrated promising antitumor activity and a manageable safety profile in previously treated patients with advanced gastric cancer, advanced metastatic microsatellite instability-high or mismatch repair colorectal cancer, and advanced biliary tract cancers

Oral Paclitaxel-Encequidar Associated With Greater Efficacy, Lower Neuropathy Rates in mBC Compared to IV Paclitaxel Alone

December 10th 2020

December 10, 2020 — Oral paclitaxel and encequidar elicited lower rates of chemotherapy-induced peripheral neuropathy, as well as greater efficacy, in patients with metastatic breast cancer compared to intravenous paclitaxel.

High-Dose Imetelstat Improves Overall Survival and Offers Clinical Benefits in High-Risk Myelofibrosis

December 5th 2020

December 5, 2020 - Patients with myelofibrosis who are relapsed after or refractory to therapy with Janus kinase inhibitors saw better overall survival, spleen response, and symptom response with higher doses of the telomerase inhibitor imetelstat.

Dose-Dense iddEPC Demonstrates Significant Benefits in HR+/HER2- Breast Cancer

September 20th 2020

Neoadjuvant chemotherapy with intense dose-dense epirubicin, paclitaxel, and cyclophosphamide demonstrated significant benefit in the treatment of patients with HR+/HER2- breast cancer.

Carfilzomib Triplet Does Not Improve Outcomes Versus Standard of Care in Newly Diagnosed Myeloma

May 29th 2020

The combination of next-generation proteasome inhibitor carfilzomib, lenalidomide, and dexamethasone did not show a superiority in progression-free survival in patients with newly diagnosed multiple myeloma when compared with the current standard of care triplet of bortezomib, lenalidomide and dexamethasone.

Low-Fat Diet Could Reduce Risk of Death From Breast Cancer

May 16th 2019

Women who eat a balanced, low-fat diet and daily portions of vegetables, fruit, and grains have a 21% lower risk of dying from breast cancer.

For This Giant of Cancer Care, a Holistic Approach Was Always in the Treatment Plan

March 20th 2019

A 2018 Giants of Cancer Care® award winner for Supportive, Palliative Geriatric Care, Patricia A. Ganz, MD has spent much of her life working to improve the quality of care for patients with cancer.

Adding Dendritic Cell-Based Immunotherapy to Chemo Improves OS in Relapsed Ovarian Cancer

March 19th 2019

The addition of the dendritic cell-based immunotherapy DCVAC/OvCA to standard carboplatin and gemcitabine led to a significant improvement in overall survival in patients with relapsed, platinum-sensitive, epithelial ovarian cancer.

Diet May Impact Response to Immunotherapy in Patients With Melanoma

February 28th 2019

Select patients with melanoma who consume a diet rich in fiber could see an improved response to treatment with immunotherapy.